Dermata Therapeutics, Inc. - Common Stock (DRMA)

SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that it will soon reveal its new brand name for its over-the-counter ("OTC") skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation. While the name remains confidential until the formal unveiling, the Company is offering a first look at the mission and essence driving this new identity-one created specifically for the community of skincare consumers who expect more from their products, their science, and the companies behind them.

- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -

- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -

- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 -

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne -

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -

- STAR-1 topline results expected in March 2025 -

SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and distribution of over-the-counter (OTC) pharmaceutical dermatology focused products that can be sold directly to consumers. This decision was informed by the knowledge gained while developing the Company's Spongilla technology as well as current market dynamics. The Company believes this transition represents a significant landmark in the Company's mission to deliver patients with safe, effective, and consumer-friendly dermatology products.

- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial-

- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -

- Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints -

- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -

- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial -

SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024 (with respect to 3,825,138 warrants) and May 2024 (with respect to 1,009,332 warrants), at a reduced exercise price of $1.284 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File Nos. 333-282223 and 333-280682). The closing of the offering is expected to occur on or about March 28, 2025, subject to satisfaction of customary closing conditions.

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -

SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,007,880 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 2,007,880 shares of common stock at a purchase price of $1.27 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrant in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The warrants will have an exercise price of $1.27 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants and will expire five years from the effective date of stockholder approval. The closing of the offering is expected to occur on or about January 23, 2025, subject to the satisfaction of customary closing conditions.

The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis -

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com –